Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis

References

• Shapira J, Peylan-Ramu N. Burkitt’s lymphoma. Oral Oncol. 1998;34(1):15–23.
   PubMed Web of Science ®Google Scholar
• Dong LH, Cheng S, Zheng Z, et al. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma. J Hematol Oncol. 2013;6(1):53.
   PubMedGoogle Scholar
• Ferry JA. Burkitt’s lymphoma: clinicopathologic features and differential diagnosis. Oncologist. 2006;11(4):375–383.
   PubMed Web of Science ®Google Scholar
• Crombie J, LaCasce A. The treatment of Burkitt lymphoma in adults. Blood. 2021;137(6):743–750.
   PubMedGoogle Scholar
• Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431–2442.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Ceribelli M, Pittaluga S, et al. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med. 2014;4(2):a14282.
   Web of Science ®Google Scholar
• Heslop HE. Sensitizing Burkitt lymphoma to EBV-CTLs. Blood. 2020;135(21):1822–1823.
   PubMed Web of Science ®Google Scholar
• Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44:1316–1320.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116–120.
   PubMed Web of Science ®Google Scholar
• Raggi C, Factor VM, Seo D, et al. Epigenetic reprogramming modulates malignant properties of human liver cancer. Hepatology. 2014;59(6):2251–2262.
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074–1080.
   PubMed Web of Science ®Google Scholar
• Gallinari P, Di Marco S, Jones P, et al. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res. 2007;17(3):195–211.
   PubMed Web of Science ®Google Scholar
• Ji H, Zhou Y, Zhuang X, et al. Correction: HDAC3 deficiency promotes liver cancer through a defect in H3K9ac/H3K9me3 transition. Cancer Res. 2020;80(4):923.
   PubMed Web of Science ®Google Scholar
• Yan Y, An J, Yang Y, et al. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN – or SPOP-mutated prostate cancer. EMBO Mol Med. 2018;10(4):1759–1768.
   Web of Science ®Google Scholar
• Li J, Hu M, Liu N, et al. HDAC3 deteriorates colorectal cancer progression via microRNA-296-3p/TGIF1/TGFβ axis. J Exp Clin Cancer Res. 2020;39(1):248.
   PubMed Web of Science ®Google Scholar
• Monroig-Bosque Pdel C, Rivera CA, Calin GA. MicroRNAs in cancer therapeutics: “from the bench to the bedside”. Expert Opin Biol Ther. 2015;15(10):1381–1385.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Huang Z, Wu X, Li J. miR-101 suppresses colon cancer cell migration through the regulation of EZH2. Rev Esp Enferm Dig. 2021;113:255–260.
   PubMed Web of Science ®Google Scholar
• Gu Z, You Z, Yang Y, et al. Inhibition of MicroRNA miR-101-3p on prostate cancer progression by regulating Cullin 4B (CUL4B) and PI3K/AKT/mTOR signaling pathways. Bioengineered. 2021;12(1):4719–4735.
   PubMed Web of Science ®Google Scholar
• Meng X, Sun Y, Liu S, et al. miR-101-3p sensitizes lung adenocarcinoma cells to irradiation via targeting BIRC5. Oncol Lett. 2021;21(4):282.
   PubMed Web of Science ®Google Scholar
• Ferreira AC, Robaina MC, Rezende LM, et al. Histone deacetylase inhibitor prevents cell growth in Burkitt’s lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101. Ann Hematol. 2014;93:983–993.
   PubMed Web of Science ®Google Scholar
• Man J, Chen L, Zhai XW, et al. Expression of p-AKT and p-mTOR in pediatric Burkitt lymphoma and their correlation with prognosis. Zhonghua Bing Li Xue Za Zhi Chinese Journal of Pathology. 2020;49:156–161.
   PubMedGoogle Scholar
• Dozzo M, Carobolante F, Donisi PM, et al. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther. 2017;8:11–29.
   PubMed Web of Science ®Google Scholar
• Białopiotrowicz E, Noyszewska-Kania M, Kachamakova-Trojanowska N, et al. Serine biosynthesis pathway supports MYC-miR-494-EZH2 feed-forward circuit necessary to maintain metabolic and epigenetic reprogramming of Burkitt lymphoma cells. Cancers (Basel). 2020;12(3):580.
   PubMed Web of Science ®Google Scholar
• Shah M, Rennoll SA, Raup-Konsavage WM, et al. A dynamic exchange of TCF3 and TCF4 transcription factors controls MYC expression in colorectal cancer cells. Cell Cycle. 2015;14(3):323–332.
   PubMed Web of Science ®Google Scholar
• Li L, Zheng YL, Jiang C, et al. HN1L-mediated transcriptional axis AP-2γ/METTL13/TCF3-ZEB1 drives tumor growth and metastasis in hepatocellular carcinoma. Cell Death Differ. 2019;26(11):2268–2283.
   PubMed Web of Science ®Google Scholar
• Slyper M, Shahar A, Bar-Ziv A, et al. Control of breast cancer growth and initiation by the stem cell-associated transcription factor TCF3. Cancer Res. 2012;72(21):5613–5624.
   PubMed Web of Science ®Google Scholar
• Friedman JM, Liang G, Liu CC, et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 2009;69(6):2623–2629.
   PubMed Web of Science ®Google Scholar
• Zhang JG, Guo JF, Liu DL, et al. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol. 2011;6(4):671–678.
   PubMed Web of Science ®Google Scholar
• Wang L, Li L, Guo R, et al. miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2. Cell Physiol Biochem. 2014;34(2):413–422.
   PubMedGoogle Scholar
• An X, Ma H, Liu Y, et al. Effects of miR-101-3p on goat granulosa cells in vitro and ovarian development in vivo via STC1. J Anim Sci Biotechnol. 2020;11(1):102.
   PubMed Web of Science ®Google Scholar
• Dal BM, Bomben R, Hernández L, et al. The MYC/miR-17-92 axis in lymphoproliferative disorders: a common pathway with therapeutic potential. Oncotarget. 2015;6(23):19381–19392.
   PubMedGoogle Scholar
• Hull EE, Montgomery MR, Leyva KJ. HDAC inhibitors as epigenetic regulators of the immune system: impacts on cancer therapy and inflammatory diseases. Biomed Res Int. 2016;2016:8797206.
   PubMed Web of Science ®Google Scholar
• Cao F, Zwinderman MRH, Dekker FJ. The process and strategy for developing selective histone deacetylase 3 inhibitors. Molecules. 2018;23(3):551.
   PubMed Web of Science ®Google Scholar